This study determined the antimicrobial susceptibilities of 186 clinical isolates of Nocardia spp. isolated in Gipuzkoa, northern Spain, between 1998 and 2009. Most isolates were recovered from respiratory samples, Nocardia nova, N. farcinica, N. cyriacigeorgica, N. abscessus, and N. carnea being the species most frequently isolated. Linezolid and amikacin were the only two antimicrobials to which all isolates were susceptible. The majority of N. flavorosea, N. carnea, and N. farcinica isolates were trimethoprim-sulfamethoxazole resistant.
This study determined the antimicrobial susceptibilities of 186 clinical isolates of Nocardia spp. isolated in Gipuzkoa, northern Spain, between 1998 and 2009. Most isolates were recovered from respiratory samples, Nocardia nova, N. farcinica, N. cyriacigeorgica, N. abscessus, and N. carnea being the species most frequently isolated. Linezolid and amikacin were the only two antimicrobials to which all isolates were susceptible. The majority of N. flavorosea, N. carnea, and N. farcinica isolates were trimethoprim-sulfamethoxazole resistant.
Nocardia species are ubiquitous in the environment and can be found worldwide as saprophytic components in water, soil, dust, decaying vegetation, and animal excrement. Only a small proportion of the currently described Nocardia species are known to be human pathogens, pulmonary nocardiosis being the most common manifestation of human disease (2) . Prior to the introduction of sulfonamides in therapy, mortality from invasive Nocardia infections was close to 100%, but current cure rates range from 50% of brain abscess cases to 90% of pleuropulmonary disease and almost 100% of skin and soft tissue disease cases (11) .
In this study, the in vitro activities of 20 antimicrobial agents against 186 clinical Nocardia isolates recovered from 178 patients between 1990 and 2009 in Gipuzkoa, northern Spain, were determined. Presumptive identification was performed according to the colony morphology on solid medium, Gram stain appearance, and positive modified acid-fast staining. Definitive species identification was performed by sequencing a fragment of the 16S rRNA gene using primers 5F (TGGAGA GTTTGATCCTGGCTCAG) and 1193R (ACGTCATCCCC GCCTTCCTC) and a finding of a sequence similarity of Ͼ99% with the sequence of a Nocardia type species. If similarities of Ͼ99% with more than one different Nocardia species were observed, species identification was done by sequencing a fragment of the hsp65 gene using the primers described by Telenti et al. (12, 13) . The sequences obtained were compared with those available at GenBank using BLAST software (http://www .ncbi.nlm.nih.gov) and with those at the leBIBI database (Bio Informatic Bacteria Identification tool; htpp://pbil.univ -lyon1.fr/bibi).
Susceptibility testing was performed by the broth microdilution method using the CLSI criteria (9) with Sensititre microtiter trays (Sensititre; Trek Diagnostics Systems, West Sussex, England) specially designed for this study and cation-adjusted Mueller-Hinton broth using the concentration range shown in Table 1 . MICs were recorded after 3 days of incubation or after 5 days for slow-growing species, such as some N. nova isolates. Because there are no CLSI interpretative criteria for Nocardia for some of the antimicrobials tested in this study, arbitrary breakpoints were used for tigecycline, moxifloxacin, clindamycin, vancomycin, and dalbavancin ( It is generally accepted that the incidence of nocardial disease is increasing (7, 10) . The development of microorganism identification based on molecular biology techniques has allowed a greater number of species within the Nocardia genus to be described (2) . Until 1995, less than 15 species were known (1), but in the last 10 years, more than 50 new species have been described. The species found in our study were those that are the most prevalent in different parts of the world (2). Other species common in tropical countries (3, 8) were very infrequent in our temperate climate region. Thus, we only found one N. otitidiscaviarum and no N. brasiliensis isolates, species that are frequently found in other regions (15) .
Currently, trimethoprim-sulfamethoxazole (SXT) remains the drug of choice in the treatment of nocardiosis, the most recent therapeutic alternative being linezolid (6, 11) . In our study, all of the N. flavorosea isolates and about half of the N. carnea and N. farcinica isolates showed SXT resistance ( Table  2) . Cercenado et al. (3) and Torres et al. (14) found 18% and 53% SXT resistance in N. farcinica isolates, respectively.
Like those in other studies (3, 5) , all of our isolates were linezolid and amikacin susceptible and most species were also imipenem susceptible, similar to the findings reported by Wallace et al. (16) . However, only 72% of N. farcinica and 39% of N. abscessus isolates were imipenem susceptible. Our isolates showed various susceptibilities to other beta-lactam antibiotics (Table 3) . Susceptibility to the different members of the tetracycline family was uneven, but only N. abscessus and N. takedensis showed high susceptibility. Because of the high proportion of resistance to fluoroquinolones, glycopeptides, vancomycin, and dalbavancin, together with the scarce experience of their use in the treatment of nocardiosis, these drugs will probably remain as alternatives when other antimicrobials cannot be used and their susceptibilities are known. Ciprofloxacin showed a species-specific susceptibility: all N. carnea isolates were susceptible, while only 18% of N. farcinica, 2% of N. nova, and none of the N. abscessus and N. cyriacigeorgica isolates were susceptible. Intrinsic activity was slightly higher for moxifloxacin than for ciprofloxacin.
Susceptibility patterns per se are not indicative of a particular species, but if associated with other phenotypic characteristics, they can suggest classification within a Nocardia species or group (Table 4) . Amoxicillin susceptibility together with amoxicillin-clavulanate resistance in slow-growing isolates suggests their membership in the N. nova complex (2, 5, 17) , although in our study, this susceptibility pattern was also characteristic of N. carnea. Rapid growth in a multiresistant strain, including cefotaxime resistance, suggests the presence of N. farcinica, of which all isolates were also clarithromycin resistant. Species of the Nocardia transvalensis complex (none in this series) have intrinsic amikacin resistance (2) (3) (4) .
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